An update on the clinical development of drugs to disable tumor vasculature

Author： Siemann Dietmar W Chaplin David J

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.2, Iss.10, 2007-10, pp. : 1357-1367

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Use of Therapies Targeting Tumor Vasculature and Stroma

Current Cancer Drug Targets, Vol. 8, Iss. 6, 2008-09 ,pp. : 498-508

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Anticancer Drugs to Tumor Vasculature Using Cationic Liposomes

By Abu Lila Amr Ishida Tatsuhiro Kiwada Hiroshi

Pharmaceutical Research, Vol. 27, Iss. 7, 2010-07 ,pp. : 1171-1183

Springer Publishing Company

Access to resources Recommend Favorite

Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects

Current Pharmaceutical Design, Vol. 18, Iss. 19, 2012-06 ,pp. : 2702-2712

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer

By Hare Jennifer I. Moase Elaine H. Allen Theresa M.

Journal of Drug Targeting, Vol. 21, Iss. 1, 2013-01 ,pp. : 87-96

Informa Healthcare

Access to resources Recommend Favorite

Clinical pharmacology in drug development — an update

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 4, 2015-07 ,pp. : 243-244

John Wiley & Sons Inc

Access to resources Recommend Favorite